We enclose a copy of the Press Release issued by Acrotech Biopharma LLC, a step-down wholly owned subsidiary of the Company on entering into a license agreement with Evive Biotech to commercialize Ryzneuta��� Ryzneuta��� Ryzneuta��� Ryzneuta��� Ryzneuta��� Ryzneuta��� (Efbemalenograstim alfa) in the US in the US in the US in the US.